Pfizer Inc


5 Best Dividend Stocks to Buy Now

There’s no better time than now to invest in dividend stocks.

And some of the best dividend stocks that beat the S&P 500’s average yield of 2.00% can be found in the healthcare sector.

Global dividends fell by 12.2% in 2020 after the pandemic forced businesses and corporations to make a total of $220 billion in dividend cuts between the second and fourth quarters of 2020.

Since then, dividend payments jumped 26% to $471.7 billion.

And dividends paid to investors are expected to pay out $1.39 trillion by the end of the year.

We only have to look at one sector to find the best combination of yields and strong balance sheets.



Why Moderna Stock Is Still a Strong Buy Now

For months, biotech companies and government officials talked about eventually needing a coronavirus booster vaccine.

Now that the Delta variant accounts for 98.8% of new U.S. infections, the possibility of wheeling out a booster is more real.

Moderna stock (NASDAQ: MRNA) got a huge pop since rolling out its initial vaccines.

It's up 466%% year-over-year.

Now, investors hope another round of vaccine distributions may fuel the company's bottom line and translate to similar gains.

They could be right…



The One mRNA Vaccine Stock to Buy Today

Pfizer, BioNTech, and Moderna investors enjoyed massive gains from late 2020 to early 2021 as the "vaccine stocks" exploded in value as their product was authorized.

Here's the thing, though – the profits aren't finished.

One company is set to experience another round of big gains over the next year or more.

Michael A. Robinson has the ticker…



This Cheap Stock Opens up a $100 Billion Medical Market

Understandably, a lot of the world's medical and scientific firepower was focused on coronavirus vaccines this year.

But other advances in medicine have the potential to do even more for investors than the "vaccine stocks" did.

Shah's looking at a potential $100 billion medical market, and sizing up a $6 stock to play it…



How to Profit in a $29 Billion “New Biotech” Sector

Back in the late 1960s and early 1970s, psychedelics drugs like LSD were still legal and could be researched.

But in 1968 when the federal government criminalized them, a lot of promising research stopped.

Now the spotlight is back on these drugs and the success they’ve shown in clinical trials for treating a range of mental health conditions.

This is not only great news for people suffering from these conditions, but also for savvy investors who’ll get in on the ground floor of a market that could be worth more than $29 billion by the end of the decade.

Here’s Shah with all the details….